| ||||||||||||||||||||||||||||||||||||||
 BioTrinity 2009 - Oxford, April 2-3, 2009 UK's Premier Biotechnology and Investment Conference Over 50 biotech and medtech investors from the US and Europe will be partnering at BioTrinity 2009 Oxford (April 2-3), including some of the biggest names in the industry: Atlas, Abingworth, Avlar, MVM, and Excalibur and corporate venturers such as GSK’s SR One, Novo A/S, Genzyme Ventures, Takeda Research Investments, and MPHVM. Early stage investors Spark, Esperante, Rainbow, Oxford Capital and Oxford Technology will also be in force meeting start-ups, as well as the newly formed Albion Ventures LLP. Investors attending have a total of $32bn under management. Four key facts about BioTrinity 2009 - Oxford
BioTrinity 2009 will also feature plenaries and panel discussions from the successful entrpreneurs John Burt, David Knowles and Ken Powell who built up and sold UK biotechnology companies Thiakis, Piramed and Arrow and returned nearly $500m of value to their investors. BioTrinity 2009 will face the challenges of the current climate head-on with key issues addressed by industry leaders. Dealing with successful deal making in the current climate, BioTrinity will draw on the experiences of key industry pharma licensing figures, including Nigel Sheail, VP Global Head of Licensing at Roche, Esteban Pombo-Villar, Head of Strategic Alliance Management at Novartis and Kate Burt, Director, Transactions at GSK, as well as Ian Nicholson, CEO of Chroma Therapeutics and Jane Dancer, Vice President Business Development at Cellzome. Dealing with successful fundraising in the current climate, BioTrinity will draw on the experiences of key VCs including Regina Hodits, Partner at Atlas Venture, which recently closed its $283m Fund VIII, as well as corporate venturers Graeme R Martin, CEO, Takeda Research Investments, Martin Edwards, Senior Partner, Novo A/S, Allison Robbins, Senior Associate, Genzyme Ventures, Sam Fazelli, Head of European Equity Research, Piper Jaffray and David Mott, Investment Director at Oxford Capital Partners who will be among over 50 investor delegates expected to attend this year. BioTrinity unites the UK’s biotech industry, and provides an ideal platform for US and European companies to partner with pharma, meet investors and European companies in the most beautiful city in England, just 1 hours' drive from Heathrow International Airport. The updated programme for BioTrinity has now been published online and can be downloaded: online ........................................................................................... Who else is attending BioTrinity 2009?
........................................................................................... What other people think:"My first time at a UK partnering conference was
BioTrinity 2008, and I did a deal with an NZ pharma as a direct
result". Allen Hakimi, Managing Director at Technomark
Life Sciences "As a direct result of our focused partnering meetings we introduced proteros to potential clients at BioTrinity 2008 which we are pleased to report resulted in several new opportunities and one of which has developed into a substantial business relationship". Gordon J Woodrow, VP at Proteros biostructures GmbH "...I would like to congratulate you on an excellent
meeting.." "...Congratulations on such a good event. I had a very productive day with lots of organized and impromptu meetings - a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma
Register online now at www.biotrinity.com ............................................................................................ BioTrinity is organised by OBN - Rapidly becoming the UK's leading biotech network
| ||||||||||||||||||||||||||||||||||||||
|
© 2006-2009 OBN |
10 of
world's top 20 global pharma represented
